Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
5.47
+0.06 (1.11%)
Aug 10, 2026, 10:42 AM EDT - Market open
Annexon Employees
Annexon had 93 employees as of March 31, 2026. The number of employees decreased by 13 or -12.26% compared to the same quarter last year.
Employees
93
Change
-13
Growth
-12.26%
Revenue / Employee
n/a
Profits / Employee
-$2,132,613
Market Cap
896.22M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 93 | -13 | -12.26% |
| Dec 31, 2025 | 96 | -4 | -4.00% |
| Sep 30, 2025 | 99 | 15 | 17.86% |
| Jun 30, 2025 | 103 | 32 | 45.07% |
| Mar 31, 2025 | 106 | 36 | 51.43% |
| Dec 31, 2024 | 100 | 29 | 40.85% |
| Sep 30, 2024 | 84 | 8 | 10.53% |
| Jun 30, 2024 | 71 | -6 | -7.79% |
| Mar 31, 2024 | 70 | -10 | -12.50% |
| Dec 31, 2023 | 71 | -9 | -11.25% |
| Sep 30, 2023 | 76 | -7 | -8.43% |
| Jun 30, 2023 | 77 | 2 | 2.67% |
| Mar 31, 2023 | 80 | 17 | 26.98% |
| Dec 31, 2022 | 80 | 19 | 31.15% |
| Sep 30, 2022 | 83 | 21 | 33.87% |
| Jun 30, 2022 | 75 | 18 | 31.58% |
| Mar 31, 2022 | 63 | 15 | 31.25% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| Geron | 258 |
| Omeros | 175 |
| Solid Biosciences | 121 |
| Aura Biosciences | 113 |
| Theravance Biopharma | 90 |
| Aclaris Therapeutics | 73 |
| SpyGlass Pharma | 68 |
ANNX News
- 4 days ago - Annexon announces tanruprubart data from FORWARD study - TheFly
- 4 days ago - Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week - GlobeNewsWire
- 10 days ago - Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - GlobeNewsWire
- 20 days ago - Annexon initiated with an Underperform at Citizens - TheFly
- 24 days ago - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Annexon price target raised to $25 from $11 at Needham - TheFly
- 26 days ago - Annexon to present vonaprument data at ASRS - TheFly
- 26 days ago - Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 - GlobeNewsWire